Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
Recruiting
Observational Study
Hematological Malignancies
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 40
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- University Children's Hospital, Zurich · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Pediatric and adult patients below the age of 40 years
* Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma
* Tumor material collected as part of routine diagnostics and willingness to donate tumor material for trans…
Contacts